S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
NASDAQ:AMRN

Amarin - AMRN Stock Forecast, Price & News

$1.56
-0.07 (-3.99%)
(As of 08/18/2022 02:46 PM ET)
Add
Compare
Today's Range
$1.56
$1.60
50-Day Range
$1.27
$1.99
52-Week Range
$1.11
$5.97
Volume
77,039 shs
Average Volume
3.27 million shs
Market Capitalization
$621.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Amarin MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
59.7% Upside
$2.50 Price Target
Short Interest
Healthy
5.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Amarin in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$92,950 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.35) to ($0.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

597th out of 1,122 stocks

Pharmaceutical Preparations Industry

298th out of 551 stocks

AMRN stock logo

About Amarin (NASDAQ:AMRN) Stock

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Analyst Upgrades and Downgrades

AMRN has been the subject of several research analyst reports. SVB Leerink downgraded shares of Amarin from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $10.00 to $3.00 in a research report on Thursday, May 5th. JPMorgan Chase & Co. downgraded shares of Amarin from a "neutral" rating to an "underweight" rating in a research report on Friday, May 6th. The Goldman Sachs Group cut their target price on shares of Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a research report on Tuesday, May 24th. Northland Securities downgraded shares of Amarin from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 4th. Finally, HC Wainwright downgraded shares of Amarin from a "buy" rating to a "neutral" rating and cut their target price for the stock from $10.00 to $3.00 in a research report on Thursday, May 5th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $2.50.

Amarin Trading Down 2.4 %

NASDAQ:AMRN opened at $1.63 on Thursday. Amarin has a 1 year low of $1.11 and a 1 year high of $5.97. The firm's fifty day simple moving average is $1.55 and its 200 day simple moving average is $2.34.

Amarin (NASDAQ:AMRN - Get Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. The firm had revenue of $94.44 million during the quarter, compared to analyst estimates of $88.21 million. During the same quarter in the previous year, the business posted $0.02 earnings per share. The business's quarterly revenue was down 38.9% compared to the same quarter last year. As a group, equities research analysts predict that Amarin will post -0.35 earnings per share for the current year.

Insider Activity at Amarin

In related news, Director Olsen Per Wold purchased 55,000 shares of Amarin stock in a transaction on Monday, June 13th. The stock was purchased at an average cost of $1.69 per share, with a total value of $92,950.00. Following the acquisition, the director now directly owns 149,000 shares in the company, valued at $251,810. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 0.90% of the stock is currently owned by company insiders.

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock News Headlines

Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.
Form S-8 AMARIN CORP PLC\UK - StreetInsider.com
Amarin Corp: Q2 Earnings Insights - Benzinga
Amarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.com
Amarin (NASDAQ:AMRN) Upgraded at StockNews.com
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Company Calendar

Last Earnings
8/03/2022
Today
8/18/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+59.7%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$7.73 million
Pretax Margin
-18.89%

Debt

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.06 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
393,435,000
Market Cap
$621.32 million
Optionable
Optionable
Beta
1.85

Social Links


Key Executives

  • Mr. Karim Mikhail (Age 51)
    Pres, CEO & Director
    Comp: $1.19M
  • Dr. Steven B. Ketchum Ph.D. (Age 57)
    Pres of R&D, Exec. VP and Chief Scientific Officer
    Comp: $827.62k
  • Mr. Jason M. Marks J.D. (Age 46)
    Exec. VP, Chief Legal and Compliance Officer & Corp. Sec.
    Comp: $626.07k
  • Mr. Joseph T. Kennedy J.D. (Age 54)
    Exec. VP of Strategic Initiatives & Gen. Counsel
    Comp: $980.18k
  • Mr. Aaron D. Berg (Age 59)
    Exec. VP & Pres of U.S.
    Comp: $745.52k
  • Mr. Thomas Charles Reilly (Age 50)
    CFO & Sr. VP
  • Dr. David Keenan
    Sr. VP of Technical Operations
  • Ms. Lisa M. DeFrancesco (Age 42)
    Sr. VP of Corp. Affairs & Investor Relations
  • Alina Kolomeyer
    Director of Communications
  • Mr. Jordan Zwick (Age 35)
    Sr. VP of Corp. Bus. Devel.













AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price forecast for 2022?

6 analysts have issued 12-month target prices for Amarin's stock. Their AMRN share price forecasts range from $1.50 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 53.4% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2022?

Amarin's stock was trading at $3.37 on January 1st, 2022. Since then, AMRN shares have decreased by 51.6% and is now trading at $1.63.
View the best growth stocks for 2022 here
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biopharmaceutical company had revenue of $94.44 million for the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative trailing twelve-month return on equity of 13.63% and a negative net margin of 21.05%. The business's revenue was down 38.9% on a year-over-year basis. During the same quarter last year, the company earned $0.02 earnings per share.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include DG Capital Management LLC (1.46%), Clearbridge Investments LLC (1.32%), SCP Investment LP (0.69%), Millennium Management LLC (0.64%), Van ECK Associates Corp (0.26%) and Jane Street Group LLC (0.00%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Lars Ekman, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.63.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $647.13 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Amarin have?

The company employs 560 workers across the globe.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
When was Amarin founded?

Amarin was founded in 1991.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.